Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsFelix Knauf, MD
Assistant Professor of Internal Medicine (Adjunct)About
Research
Publications
2025
SLC26A1 directs sulfate homeostasis in health and disease
Pitzken F, Köttgen A, Aronson P, Knauf F. SLC26A1 directs sulfate homeostasis in health and disease. Current Opinion In Nephrology & Hypertension 2025, 35: 126-132. PMID: 41056011, DOI: 10.1097/mnh.0000000000001123.Peer-Reviewed Original ResearchConceptsOxalate homeostasisMouse modelKidney stone diseaseSulfate homeostasisStone diseaseOxalate transportTissue-specific gene deletionAcetaminophen-induced liver injuryKnockout mouse modelSulfation of proteoglycansDamaging variantsClinical outcomesMusculoskeletal abnormalitiesLiver injuryGene deletionHuman diseasesDisease pathogenesisSkeletal integrityAssociated diseasesCell functionSlc26a1DiseaseKidneyFunctional assaysHomeostasisEffects of Tissue-Specific Slc26a1 Deletion on Sulfate Homeostasis
Zimmermann A, Jiang Z, Thomson R, Knauf F, Aronson P. Effects of Tissue-Specific Slc26a1 Deletion on Sulfate Homeostasis. Journal Of The American Society Of Nephrology 2025, 36: 10.1681/asn.2025xyj8y4mn. DOI: 10.1681/asn.2025xyj8y4mn.Peer-Reviewed Original ResearchSulfate Transporter SLC26A1 Is Crucial for Musculoskeletal Health
Pitzken F, Fretz J, Jiang Z, Zimmermann A, Westendorf J, Aronson P, Knauf F. Sulfate Transporter SLC26A1 Is Crucial for Musculoskeletal Health. Journal Of The American Society Of Nephrology 2025, 36: 10.1681/asn.2025fzfa7mm4. DOI: 10.1681/asn.2025fzfa7mm4.Peer-Reviewed Original ResearchShift Work and the Risk of Kidney Stones
Knauf F, Luft F, Nath K. Shift Work and the Risk of Kidney Stones. Mayo Clinic Proceedings 2025, 100: 1693-1695. PMID: 41031993, DOI: 10.1016/j.mayocp.2025.08.018.Peer-Reviewed Original ResearchComparison of Patients with Primary Hyperoxaluria 1 and Late-Stage CKD from the BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial
Lieske J, Baum M, Benshalom E, Belostotsky V, Knauf F, Sellier-Leclerc A, Du W, Callanan M, Kauf T, Murphy M, Groothoff J. Comparison of Patients with Primary Hyperoxaluria 1 and Late-Stage CKD from the BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial. Journal Of The American Society Of Nephrology 2025, 36: 10.1681/asn.2025b26anqr1. DOI: 10.1681/asn.2025b26anqr1.Peer-Reviewed Original ResearchUrine Oxalate Excretion and CKD Stage in Patients With Primary Hyperoxaluria Type 1
Vaughan L, Schulte P, Knauf F, Sas D, Milliner D, Lieske J. Urine Oxalate Excretion and CKD Stage in Patients With Primary Hyperoxaluria Type 1. American Journal Of Kidney Diseases 2025, 87: 138-140. PMID: 40983145, PMCID: PMC12462907, DOI: 10.1053/j.ajkd.2025.07.013.Peer-Reviewed Original ResearchCoupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits
Scherer N, Fässler D, Borisov O, Cheng Y, Schlosser P, Wuttke M, Haug S, Li Y, Telkämper F, Patil S, Meiselbach H, Wong C, Berger U, Sekula P, Hoppmann A, Schultheiss U, Mozaffari S, Xi Y, Graham R, Schmidts M, Köttgen M, Oefner P, Knauf F, Eckardt K, Grünert S, Estrada K, Thiele I, Hertel J, Köttgen A. Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nature Genetics 2025, 57: 193-205. PMID: 39747595, PMCID: PMC11735408, DOI: 10.1038/s41588-024-01965-7.Peer-Reviewed Original ResearchConceptsWhole-exome sequencing dataGene-metabolite associationsHuman traitsHuman metabolic reactionsSequence dataAllelic seriesGene functionExome sequencingFunctional variantsGenetic studiesInborn errors of metabolismHeterozygous variantsErrors of metabolismMusculoskeletal traitsMetabolic reactionsHuman heightUrine metabolitesHeterozygous stateSulfate reabsorptionInborn errorsTraitsAggregation testVariantsHuman metabolismMetabolomics
2024
Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients
Hardenberg J, Kunz J, Rubarth K, Mittermaier M, Pigorsch M, Balzer F, Witzenrath M, Hinz R, Körner R, Eckardt K, Knauf F, Hinrichs C, Enghard P. Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients. Clinical Kidney Journal 2024, 17: sfae328. PMID: 39582778, PMCID: PMC11584513, DOI: 10.1093/ckj/sfae328.Peer-Reviewed Original ResearchGlucose 5% solutionGlucose 5%Severe hypernatremiaDrug diluentDrug solventSodium concentrationAssociated with increased mortalityResults Baseline characteristicsAdult COVID-19 patientsRetrospective before-and-after studyCritically ill patientsIntensive care unitPre-emptive usePrevalence of hypernatremiaStudy intensive care unitVenous blood gasesLength of stayCOVID-19 patientsBaseline characteristicsClinical outcomesICU admissionHypernatremiaMedical ICUCare unitBlood gasesOpportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory
Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S, Knauf F, Knight J, Lieske J, Lowther W, Moochhala S, Nazzal L, Tasian G, Whittamore J, Sas D. Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory. Kidney International Reports 2024, 9: 3083-3096. PMID: 39534212, PMCID: PMC11551133, DOI: 10.1016/j.ekir.2024.08.031.Peer-Reviewed Original ResearchPrimäre Hyperoxalurie
Saadé C, Knauf F. Primäre Hyperoxalurie. Nephrologie Aktuell 2024, 28: 272-278. DOI: 10.1055/a-2270-5042.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Get In Touch
Contacts
Email